Merck, a science and technology company, announced the winners of its Advance Biotech Grant program in Taiwan. The first prize went to Mycenax.
Applicants from biotech companies in Taiwan were asked to describe their projects such as the medical needs they solved and process development challenges they faced. In support of the growing biotech ecosystem, grant recipients received the products and process development support that are equivalent to NT$16,000,000. Mycenex won the NT$4,600,000 with the honor of the first prize winner.
Merck selected the winners based on the expertise with the scientific and societal merit of therapy in development and process challenges. Therefore, with this glory and compliment, Mycenax will keep providing our client state of the art technology to meet all their demands and be their flexible and professional partner.
“Mycenax is honored to be selected as the first place in the Advance Biotech Grant,” said Leo Su, Vice president of Mycenax. “Under the resources provided by this grant, we intend to optimize a robust and scalable continuous process that can link the process of upstream and downstream more smoothly.”
Mycenax is the first Taiwan leading pharmaceutical company with one-stop biopharmaceutical capabilities and technology development platforms. In recent years, Mycenax has continuously strengthened the CDMO research and development energy to assisted European, American, and Japanese customers to develop protein drugs with single-use technology for over ten years. Furthermore, Mycenax has engaged in a partnership with Dutch business developers to advance the continuous process in recent years and become the world’s first new drug developer who utilizes the process to pass clinical applications. Mycenax has commissioned development projects to internationally renowned pharmaceutical companies and has carried out phase I clinical trial and phase III clinical trial, indicating that Mycenax is highly recognized by the capability and technologies.
Merck, a science and technology company, announced the winners of its Advance Biotech Grant program in Taiwan. The first prize went to Mycenax.
Applicants from biotech companies in Taiwan were asked to describe their projects such as the medical needs they solved and process development challenges they faced. In support of the growing biotech ecosystem, grant recipients received the products and process development support that are equivalent to NT$16,000,000. Mycenex won the NT$4,600,000 with the honor of the first prize winner.
Merck selected the winners based on the expertise with the scientific and societal merit of therapy in development and process challenges. Therefore, with this glory and compliment, Mycenax will keep providing our client state of the art technology to meet all their demands and be their flexible and professional partner.
“Mycenax is honored to be selected as the first place in the Advance Biotech Grant,” said Leo Su, Vice president of Mycenax. “Under the resources provided by this grant, we intend to optimize a robust and scalable continuous process that can link the process of upstream and downstream more smoothly.”
Mycenax is the first Taiwan leading pharmaceutical company with one-stop biopharmaceutical capabilities and technology development platforms. In recent years, Mycenax has continuously strengthened the CDMO research and development energy to assisted European, American, and Japanese customers to develop protein drugs with single-use technology for over ten years. Furthermore, Mycenax has engaged in a partnership with Dutch business developers to advance the continuous process in recent years and become the world’s first new drug developer who utilizes the process to pass clinical applications. Mycenax has commissioned development projects to internationally renowned pharmaceutical companies and has carried out phase I clinical trial and phase III clinical trial, indicating that Mycenax is highly recognized by the capability and technologies.